Bristol Claims A First With Opdivo In Neoadjuvant NSCLC

Co-Primary Endpoint Data May Support Early Approval

 
• By Mandy Jackson
  
closeup of a young caucasian doctor man sitting at his office desk observing a chest radiograph in a tablet computer
Opdivo plus chemo had higher response rates in neoadjuvant lung cancer than chemo alone • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer